Hyplaxy

Hydroxychloroquine Sulfate, the active ingredient in Hyplaxy, is an antimalarial presented as an oral tablet for oral use. It is employed to treat malaria and to manage autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus in adult patients.

GNH USA supplies Hyplaxy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers. All batches are manufactured under EU GMP guidelines and undergo rigorous testing before release.

Hydroxychloroquine Sulfate is used in the treatment of parasitic infections and autoimmune diseases. - Malaria: Reduces parasitic load and prevents disease progression. - Rheumatoid arthritis: Decreases joint inflammation and slows disease progression. - Systemic lupus erythematosus: Controls disease activity and reduces flare frequency.

Hydroxychloroquine Sulfate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Diarrhea: loose stools. - Skin rash: mild erythema or itching. - Visual disturbance: blurred vision or difficulty focusing.

Serious or Rare Side Effects: - Retinal toxicity: irreversible vision loss requiring ophthalmologic monitoring. - Cardiac arrhythmia: QT prolongation and potential ventricular tachycardia. - Severe hypoglycemia: especially in diabetic patients on insulin. - Hemolytic anemia: in individuals with G6PD deficiency. - Neuropsychiatric effects: agitation, confusion or mood changes.

Before prescribing Hydroxychloroquine Sulfate, clinicians should consider several safety measures. - Baseline eye exam: obtain ophthalmologic assessment prior to therapy. - Cardiac monitoring: evaluate ECG for QT interval in patients with cardiac risk. - Renal function: adjust dose if significant impairment is present. - Concomitant medications: review for drugs that may prolong QT interval. - Pregnancy and lactation: weigh potential risks against benefits; use only if clearly indicated. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Hydroxychloroquine Sulfate interacts with several medicines, requiring careful management.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of hydroxychloroquine. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly decrease drug levels. - QT‑prolonging agents (e.g., quinidine, amiodarone): increase risk of cardiac arrhythmias. - Digoxin: may increase serum digoxin concentrations. - Azithromycin: combined use heightens QT prolongation risk.

Moderate Interactions (Monitor Closely): - Antimalarial combination (e.g., artesunate): potential additive toxicity. - Anticoagulants (warfarin): may enhance anticoagulant effect. - Antidiabetic agents (insulin, sulfonylureas): increase risk of hypoglycemia. - Corticosteroids: may augment immunosuppressive effect.